Trial intelligence / Profile preview

Sofosbuvir/Velpatasvir in Chronic HCV

NCT02722837Phase 3Completed

Sponsor
Gilead Sciences
Start
Apr 2016
Primary completion
Jun 2017
Modality
Small Molecules
Countries
2
01

Overview

A Phase 3 trial of sofosbuvir + velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Apr 2016; status: completed.

02

Drugs

sofosbuvir + velpatasvir
03

Conditions

hepatitis C (HCV)

Beyond the preview

Go deeper on NCT02722837.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02722837.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call